Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc., a leading biotechnology company headquartered in the United States, focuses on the development of innovative therapies for cancer treatment. Founded in 2010, Mirati has made significant strides in the oncology sector, particularly in targeted therapies and precision medicine.
The company is renowned for its core products, including novel small molecule inhibitors that address specific genetic mutations in tumours, setting it apart in a competitive landscape. With a strong emphasis on research and development, Mirati has achieved notable milestones, including advancing multiple candidates into clinical trials.
As a key player in the biotechnology industry, Mirati Therapeutics continues to enhance its market position through strategic partnerships and a commitment to transforming cancer care, making it a pivotal entity in the fight against cancer.
+38 vs industry average
Mirati Therapeutics, Inc.’s score of 77 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Mirati Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Mirati Therapeutics, Inc. yet.
Mirati Therapeutics, Inc.'s reported carbon emissions
Mirati Therapeutics, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Bristol-Myers Squibb Company, which influences its climate commitments and initiatives.
Mirati's climate strategy is informed by the sustainability efforts of its parent company, Bristol-Myers Squibb. This includes participation in various climate initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded from Bristol-Myers Squibb. However, specific reduction targets or achievements for Mirati Therapeutics are not detailed in the available data.
As part of its corporate family, Mirati is aligned with industry-standard climate terminology and practices, although it has not set its own distinct reduction targets or climate pledges at this time. The company's commitment to sustainability is thus closely linked to the broader initiatives of Bristol-Myers Squibb, reflecting a collective approach to addressing climate change within the pharmaceutical sector.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Mirati Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Mirati Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Bristol-Myers Squibb Company
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Bristol-Myers Squibb Company
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Mirati Therapeutics, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project